Pfizer (NYSE:PFE) Trading 1.3% Higher – Time to Buy?

Pfizer Inc. (NYSE:PFE)’s stock price shot up 1.3% during trading on Wednesday . The stock traded as high as $25.95 and last traded at $25.8410. 95,636,721 shares traded hands during mid-day trading, an increase of 89% from the average session volume of 50,615,055 shares. The stock had previously closed at $25.51.

Analysts Set New Price Targets

Several equities analysts recently weighed in on PFE shares. Bank of America lifted their target price on Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research report on Friday, October 3rd. Sanford C. Bernstein reiterated a “market perform” rating and set a $30.00 price objective on shares of Pfizer in a research note on Friday, October 31st. UBS Group reissued a “neutral” rating and issued a $28.00 target price on shares of Pfizer in a report on Wednesday, October 1st. Citigroup lifted their price target on shares of Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a report on Wednesday, August 6th. Finally, The Goldman Sachs Group reissued a “neutral” rating and issued a $26.00 price objective on shares of Pfizer in a research note on Wednesday, November 5th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $28.18.

Pfizer Stock Up 1.3%

The business has a 50-day moving average price of $24.75 and a 200 day moving average price of $24.41. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. The stock has a market capitalization of $146.92 billion, a P/E ratio of 13.75, a P/E/G ratio of 0.81 and a beta of 0.54.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.79 by $0.08. The firm had revenue of $16.65 billion for the quarter, compared to analysts’ expectations of $16.94 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. On average, equities analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 7th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.7%. The ex-dividend date is Friday, November 7th. Pfizer’s dividend payout ratio is presently 100.00%.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Capital Advisory Group Advisory Services LLC grew its stake in Pfizer by 2.9% in the second quarter. Capital Advisory Group Advisory Services LLC now owns 13,542 shares of the biopharmaceutical company’s stock valued at $328,000 after acquiring an additional 388 shares during the period. Citizens National Bank Trust Department lifted its holdings in shares of Pfizer by 0.9% in the 2nd quarter. Citizens National Bank Trust Department now owns 46,103 shares of the biopharmaceutical company’s stock worth $1,118,000 after purchasing an additional 395 shares in the last quarter. Peak Asset Management LLC grew its position in Pfizer by 1.4% in the 2nd quarter. Peak Asset Management LLC now owns 28,768 shares of the biopharmaceutical company’s stock valued at $697,000 after purchasing an additional 402 shares during the period. Community Bank & Trust Waco Texas increased its stake in Pfizer by 0.6% during the 3rd quarter. Community Bank & Trust Waco Texas now owns 66,841 shares of the biopharmaceutical company’s stock valued at $1,703,000 after purchasing an additional 412 shares in the last quarter. Finally, Able Wealth Management LLC increased its stake in Pfizer by 2.0% during the 2nd quarter. Able Wealth Management LLC now owns 21,128 shares of the biopharmaceutical company’s stock valued at $512,000 after purchasing an additional 413 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.